FDA
-
-
-
-
-
-
-
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
-
-
-
-
-
-
-
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
-
-
-
-
-
-
-
Tonix presents phase 1 data for Lyme disease prevention drug TNX-4800
-
-
-
-
-
-
-
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
-
-
-
-
-
-
-
Tonix Pharmaceuticals prices $20 million registered direct offering
-
-
-
-
-
-
-
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
-
-
-
-
-
-
-
Tonix partners with Mass General for kidney transplant drug trial
-
323,147 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

